Cite
HARVARD Citation
Herbst, R. et al. (n.d.). LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Annals of oncology. p. . [Online].